

Supplementary Information

Table S1. Results of plasma biomarker screening.

Biomarker	Unit	Detection Limit	MRL	LPR	Significance
Apo A-I	µg/mL	1.4	25.7 ± 1.1	27.3 ± 1.0	n.s.
CD40	pg/mL	5.3	70.6 ± 6.7	67.2 ± 7.7	n.s.
CD40-L	pg/mL	508	1702.9 ± 286.8	2552.7 ± 288.9	p = 0.02
C-reactive protein (CRP)	µg/mL	0.86	4.9 ± 0.2	4.9 ± 0.2	n.s.
Eotaxin	pg/mL	5	620.6 ± 34.8	728.4 ± 60.0	n.s.
Epidermal growth factor (EGF)	pg/mL	9.3	681.5 ± 195.5	403.0 ± 140.4	n.s.
Factor VII	ng/mL	28	42.3 ± 0.8	41.6 ± 0.7	n.s.
Fibrinogen	mg/mL	0.178	59.1 ± 4.3	65.0 ± 3.6	n.s.
Fibroblast growth factor-basic (FGF-basic)	ng/mL	23	23.6 ± 0.9	21.3 ± 0.6	p = 0.02
Granulocyte chemotactic protein-2 (GCP-2)	ng/mL	0.38	4.2 ± 0.4	4.2 ± 0.3	n.s.
Haptoglobin	µg/mL	3.6	35.5 ± 1.4	50.0 ± 3.7	*
Immunoglobulin A (IgA)	µg/mL	3.7	609.5 ± 47.2	3620 ± 502.5	*
Interferon-γ	pg/mL	1	u.d.	2.6	n.a.
Interferon-γ inducible protein 10 (IP-10)	pg/mL	5.1	107.7 ± 6.2	202.9 ± 16.3	*
IL-1α	pg/mL	30	864.0 ± 206.1	499.1 ± 145.3	n.s.
IL-1β	ng/mL	6	7.2 ± 0.4	5.7 ± 0.4	p = 0.03
IL-5	ng/mL	0.41	u.d.	0.35 ± 0.05	n.a.
IL-7	ng/mL	0.13	0.14 ± 0.02	0.13 ± 0.02	n.s.
IL-10	pg/mL	1	4.7 ± 1.9	34.0 ± 4.0	*
IL-18	ng/mL	4.3	20.4 ± 0.9	20.0 ± 0.5	n.s.
Leukemia inhibitory factor (LIF)	pg/mL	707	1820.0 ± 48.2	1974.8 ± 45.8	p = 0.02
Lymphotactin	pg/mL	9.9	74.7 ± 3.5	169.9 ± 6.7	*
Macrophage colony-stimulating factor-1 (M-CSF-1)	ng/mL	0.0088	5.2 ± 0.2	4.7 ± 0.1	n.s.
Macrophage inflammatory protein-1α (MIP-1α)	ng/mL	2.9	7.6 ± 0.3	6.6 ± 0.2	p = 0.006
Macrophage inflammatory protein-1β (MIP-1β)	pg/mL	29	168.2 ± 13.1	206.9 ± 9.2	p = 0.01
Macrophage inflammatory protein-1γ (MIP-1γ)	ng/mL	0.92	36.8 ± 1.8	30.6 ± 2.0	p = 0.03
Macrophage inflammatory protein-2 (MIP-2)	pg/mL	6	6.8 ± 0.9	4.5 ± 0.4	p = 0.04
Macrophage inflammatory protein-3β (MIP-3β)	ng/mL	0.22	3.5 ± 0.3	12.4 ± 1.4	*

Table S1. *Cont.*

Biomarker	Unit	Detection limit	MRL	LPR	Significance
Macrophage-derived chemokine (MDC)	pg/mL	44	902.8 ± 56.3	1077.2 ± 81.5	n.s.
Matrix metalloproteinase-9 (MMP-9)	ng/mL	7.8	52.8 ± 5.4	49.9 ± 4.8	n.s.
Monocyte chemotactic protein-1 (MCP-1)	pg/mL	3.8	45.0 ± 3.7	70.9 ± 4.7	*
Monocyte chemotactic protein-3 (MCP-3)	pg/mL	5.2	88.5 ± 7.2	127.4 ± 10.2	*
Monocyte chemotactic protein-5 (MCP-5)	pg/mL	2.3	14.9 ± 1.1	23.7 ± 1.9	*
Myeloperoxidase (MPO)	ng/mL	0.61	151.4 ± 14.8	166.5 ± 13.2	n.s.
Myoglobin	ng/mL	6.8	1217.8 ± 276.5	286.9 ± 47.3	*
Serum amyloid P-component (SAP)	µg/mL	2.3	27.4 ± 1.3	29.0 ± 1.3	n.s.
Serum glutamic oxaloacetic transaminase (SGOT)	µg/mL	53	1478.2 ± 188.7	318.9 ± 19.9	*
Stem cell factor (SCF)	pg/mL	19	220.6 ± 26.9	211.2 ± 21.1	n.s.
RANTES	pg/mL	0.073	u.d.	0.089 ± 0.014	n.a.
Thrombopoietin (TPO)	ng/mL	22	34.8 ± 1.3	33.9 ± 2.3	n.s.
Tissue factor (TF)	ng/mL	3.6	6.1 ± 0.4	6.0 ± 0.3	n.s.
Tissue inhibitor of metalloproteinases 1 (TIMP-1)	ng/mL	0.041	0.8 ± 0.0	1.0 ± 0.1	p = 0.03
Vascular cell adhesion molecule-1 (VCAM-1)	ng/mL	2.8	1643.5 ± 78.0	2163.8 ± 136.2	*
Vascular endothelial growth factor A (VEGF-A)	pg/mL	24	8823.2 ± 4093.2	7345.0 ± 3384.7	n.s.
von Willebrand factor (vWF)	ng/mL	15	103.7 ± 19.7	59.5 ± 6.0	n.s.

Plasma biomarkers were measured using multiplex assays. $n = 16$ – 20 per group. Wilcoxon Test (non-parametric equivalent of t -test) with Bonferroni correction was used to compare MRL+/+ (MRL, control) and MRL/lpr (LPR, lupus) mice. Biomarkers with significant (*, $p < 0.0026$) or substantially elevated differences (exact p value) between LPR and MRL are highlighted using bold font. u.d.: undetectable; n.s.: not significant; n.a.: cannot be calculated.

Table S2. Results of tryptophan metabolite analysis.

Metabolite	Unit	Frontal Cortex			Hippocampus		
		MRL	LPR	Significance	MRL	LPR	Significance
Tryptophan (TRP)	ng/mg	10.69 ± 0.38	11.53 ± 0.35	n.s.	10.83 ± 0.23	13.28 ± 0.89	n.s.
5-Hydroxytryptophan (5-HTP)	pg/mg	1.97 ± 0.07	2.66 ± 0.21	<i>p</i> = 0.0021	17.16 ± 1.11	23.63 ± 1.52	<i>p</i> = 0.0048
5-Hydroxytryptamine (5-HT, serotonin)	pg/mg	304.65 ± 42.94	265.31 ± 74.69	n.s.	172.02 ± 61.83	301.43 ± 55.20	*
5-Hydroxyindoleacetic acid (5-HIAA)	pg/mg	1383.49 ± 49.00	1569.44 ± 88.74	n.s.	540.80 ± 101.32	950.86 ± 121.30	<i>p</i> = 0.025
Kynurenine (KYN)	pg/mg	17.47 ± 0.82	41.27 ± 2.80	*	30.61 ± 2.40	60.69 ± 4.75	*
Kynurenic acid (KYNA)	pg/mg	0.44 ± 0.02	0.53 ± 0.02	<i>p</i> = 0.008	0.67 ± 0.06	0.86 ± 0.1	n.s.
Anthranilic acid (AA)	pg/mg	0.32 ± 0.03	0.41 ± 0.02	n.s.	0.63 ± 0.08	0.61 ± 0.06	n.s.
3-Hydroxykynurenine (3-HK)	pg/mg	95.77 ± 3.99	221.37 ± 7.77	*	80.66 ± 8.98	170.07 ± 9.78	*
Xanthurenic acid (XA)	pg/mg	0.44 ± 0.02	0.46 ± 0.01	n.s.	1.10 ± 0.06	1.26 ± 0.05	n.s.
3-Hydroxyanthranilic acid (3-HAA)	pg/mg	1.61 ± 0.04	2.92 ± 0.20	*	0.81 ± 0.06	1.07 ± 0.07	<i>p</i> = 0.0062
Quinolinic acid (QA)	pg/mg	4.87 ± 0.27	14.09 ± 0.93	*	4.93 ± 0.75	22.18 ± 6.47	<i>p</i> = 0.0048
Nicotinamide (NTA)	ng/mg	64.32 ± 0.86	64.37 ± 1.62	n.s.	46.11 ± 1.13	49.28 ± 1.58	n.s.

Tryptophan metabolites in brain homogenate derived from frontal cortex or hippocampus were measured using HPLC (*n* = 9–10 per group). Wilcoxon test with Bonferroni correction was used for statistical analysis. Metabolites with significant difference (*, *p* < 0.0021) or close significant difference (exact *p*-values shown) between MRL/lpr (LPR, lupus) and MRL+/+ (MRL, control) mice are highlighted using bold font. n.s.: not significant.